CONMED (NYSE:CNMD) Updates FY 2026 Earnings Guidance

CONMED (NYSE:CNMD) updated its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 4.480-4.600 for the period, compared to the consensus estimate of 4.370. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. BMO Capital Markets assumed coverage on shares of CONMED in a report on Wednesday, July 8th. They issued a “market perform” rating and a $36.00 price objective on the stock. Wall Street Zen upgraded shares of CONMED from a “hold” rating to a “buy” rating in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d)” rating on shares of CONMED in a research report on Thursday, June 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research report on Monday, July 13th. Finally, Bank of America reiterated an “underperform” rating and set a $40.00 target price on shares of CONMED in a research note on Monday, June 29th. Five research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $38.80.

CONMED Stock Performance

NYSE CNMD traded down $1.07 during trading on Wednesday, reaching $43.18. The company’s stock had a trading volume of 761,778 shares, compared to its average volume of 558,570. The firm has a 50 day moving average price of $36.76 and a 200 day moving average price of $38.40. CONMED has a 12 month low of $31.44 and a 12 month high of $56.63. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of 24.39, a price-to-earnings-growth ratio of 3.22 and a beta of 0.93. The company has a current ratio of 2.29, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85.

CONMED (NYSE:CNMD) last announced its earnings results on Wednesday, July 29th. The company reported $1.38 EPS for the quarter, topping the consensus estimate of $1.10 by $0.28. CONMED had a net margin of 4.00% and a return on equity of 13.84%. The company had revenue of $343.49 million for the quarter, compared to analysts’ expectations of $337.60 million. CONMED has set its FY 2026 guidance at 4.480-4.600 EPS. As a group, equities analysts anticipate that CONMED will post 4.38 EPS for the current fiscal year.

Hedge Funds Weigh In On CONMED

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its stake in CONMED by 19.9% during the first quarter. AQR Capital Management LLC now owns 14,199 shares of the company’s stock worth $857,000 after acquiring an additional 2,357 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of CONMED by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,354 shares of the company’s stock valued at $1,108,000 after purchasing an additional 800 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of CONMED by 5.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 82,686 shares of the company’s stock valued at $4,993,000 after purchasing an additional 4,565 shares during the last quarter. Intech Investment Management LLC grew its holdings in shares of CONMED by 34.6% during the 1st quarter. Intech Investment Management LLC now owns 22,505 shares of the company’s stock valued at $1,359,000 after purchasing an additional 5,780 shares during the last quarter. Finally, Creative Planning bought a new stake in shares of CONMED during the 2nd quarter valued at approximately $310,000.

About CONMED

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.